The human papilloma virus (HPV) market is projected to grow at a CAGR of 14.68% during the forecasted period to reach a market size of US$5,296.808 million by 2027, from US$2,030.136 million in 2020.
Along with other immunizations, routine vaccination is advised for all nations according to WHO guidelines. The Human Papilloma Virus (HPV) vaccine offers defense against specific strains of the virus that can cause genital warts or cancer. Along with other immunizations, routine vaccination is advised for all nations according to WHO guidelines. These vaccinations are regarded as safe and effective medications and are included on the "World Health Organization's list of Essential Medicines." The global market for the Human Papilloma Virus (HPV) vaccine is being boosted by the rise in cervical cancer cases. Increased government measures will increase public awareness of HPV and cervical cancer, which will help the market for HPV vaccines. However, a stringent regulatory licensing procedure for the vaccines may limit market expansion.
Effectiveness of HPV Vaccines to Boost Sales
The effectiveness and protection offered by HPV vaccines to lessen the negative effects associated with such infections are one of the most important and significant market drivers. Clinical trials have demonstrated the effectiveness and safety of both bivalent and polyvalent vaccinations in preventing HPV infections and cancer. Additionally, it is projected that the rising incidence of cervical cancer in various nations would boost sales of the human papillomavirus vaccine, resulting in a stellar market expansion. The market is also being driven by an increase in HPV vaccination production capacity to keep global supply and demand in balance.
Geographically, the Human Papilloma Virus Vaccine Market is segmented as North America, South America, Europe, the Middle East and Africa, and Asia Pacific. North America holds major share of the market whereas Asia-Pacific is anticipated to have a faster-growing market.
Frequently Asked Questions (FAQs)
Q1. What will be the human papilloma virus (HPV) vaccine market size by 2027?
A1. The global human papilloma virus (HPV) vaccine market is projected to reach a total market size of US$5,296.808 million by 2027.
Q2. What is the size of the global human papilloma virus vaccine market?
A2. Human Papilloma Virus (HPV) Vaccine Market was valued at US$2,030.136 million in 2020.
Q3. What are the growth prospects for the human papilloma virus vaccine market?
A3. The global human papilloma virus (HPV) market is projected to grow at a CAGR of 14.68% during the forecast period.
Q4. Which region holds the largest share of the human papilloma virus vaccine market?
A4. North America holds a major share of the human papilloma virus (HPV) vaccine market.
Q5. What factors are anticipated to drive the human papillomavirus vaccine market growth?
A5. The global human papilloma virus (HPV) vaccine market is being boosted by the rise in cervical cancer cases.
1.1. Market Overview
1.2. COVID-19 Scenario
1.3. Market Definition
1.4. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. HUMAN PAPILLOMA VIRUS VACCINE MARKET ANALYSIS, BY TYPE
5.2. Quadrivalent HPV Vaccine
5.3. Bivalent HPV vaccine
5.4. 9-Valent HPV Vaccine
6. HUMAN PAPILLOMA VIRUS VACCINE MARKET ANALYSIS, BY INDICATION
6.2. Cervical Cancer
6.3. Anal Cancer
6.4. Vaginal Cancer
6.5. Vulvar Cancer
6.6. Genital Cancer
7. HUMAN PAPILLOMA VIRUS VACCINE MARKET ANALYSIS, BY GENDER
8. HUMAN PAPILLOMA VIRUS VACCINE MARKET ANALYSIS, BY GEOGRAPHY
8.2. North America
8.3. South America
8.4.3. United Kingdom
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.6. Asia Pacific
8.6.4. South Korea
9. COMPETITIVE INTELLIGENCE
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. COMPANY PROFILES
10.1. Merck & Co., Inc.
10.2. GSK plc
10.3. INOVIO Pharmaceuticals
Merck & Co Inc.
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.